XML 42 R64.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Segment Reporting (Details) (USD $)
In Millions
3 Months Ended 6 Months Ended
Jun. 30, 2011
Jun. 30, 2010
Jun. 30, 2011
Jun. 30, 2010
Dec. 31, 2010
Reconciliation from Segment Totals to Consolidated [Line Items]          
Product Sales $ 993.3 $ 764.3 $ 1,882.6 $ 1,482.4  
Royalties 63.4 82.7 137.0 178.0  
Other Revenues 6.2 2.4 15.5 5.1  
Revenues 1,062.9 849.4 2,035.1 1,665.5  
Cost of Product Sales 143.7 [1] 119.1 [1] 268.2 221.0  
Research and Development 176.9 147.0 354.8 278.0  
Selling, General and Administrative 440.3 [1] 354.4 [1] 843.2 714.3  
Loss/(gain) on sale of product rights 2.2 (4.1) 3.5 (4.1)  
Reorganization Cost 7.5 8.6 13.0 13.6  
Integration and Acquisition Cost 9.0 0 2.6 0.6  
Total operating expenses 779.6 625.0 1,485.3 1,223.4  
Operating Income (Loss) 283.3 224.4 549.8 442.1  
Assets 6,165.6 4,868.9 6,165.6 4,868.9 5,387.6
Long-Lived Assets 908.9 805.7 908.9 805.7  
Capital Expenditure on Long-Lived Assets 50.9 166.7 94.8 196.4  
Depreciation and Amortization, by Report Line          
Cost of Product Sales, Depreciation, Manufacturing Plant 10.5 9.8 18.2 18.4  
Cost of Product Sales, Amortization, Favorable Manufacturing Contract 0.4 0.4 0.9 0.9  
Research and Development Expense, Depreciation of Research and Development Asset 6.1 3.5 10.8 7.2  
Selling, General and Administrative Expense, Depreciation and Amortization 51.8 50.4 102.4 101.3  
Specialty Pharmaceuticals
         
Reconciliation from Segment Totals to Consolidated [Line Items]          
Product Sales 676.7 551.3 1,292.8 1,092.6  
Royalties 51.8 44.2 89.3 102.8  
Other Revenues 4.7 0.5 12.3 1.2  
Revenues 733.2 596.0 1,394.4 1,196.6  
Cost of Product Sales 94.1 84.6 176.0 165.0  
Research and Development 105.1 84.8 207.8 158.7  
Selling, General and Administrative 294.7 236.6 561.3 486.1  
Loss/(gain) on sale of product rights 2.2 (4.1) 3.5 (4.1)  
Reorganization Cost 2.7 3.3 5.0 6.7  
Integration and Acquisition Cost 9.0 0 2.6 0.6  
Total operating expenses 507.8 405.2 956.2 813.0  
Operating Income (Loss) 225.4 190.8 438.2 383.6  
Assets 3,555.3 2,081.5 3,555.3 2,081.5  
Long-Lived Assets 174.9 169.5 174.9 169.5  
Capital Expenditure on Long-Lived Assets 18.2 2.7 23.1 5.0  
Human Genetic Therapies
         
Reconciliation from Segment Totals to Consolidated [Line Items]          
Product Sales 316.6 213.0 589.8 389.8  
Royalties 0 0 0 0  
Other Revenues 0.2 0.6 0.5 1.3  
Revenues 316.8 213.6 590.3 391.1  
Cost of Product Sales 49.6 34.5 92.2 56.0  
Research and Development 71.8 62.2 147.0 119.3  
Selling, General and Administrative 91.9 61.9 172.0 124.7  
Loss/(gain) on sale of product rights 0 0 0 0  
Reorganization Cost 0 0 0 0  
Integration and Acquisition Cost 0 0 0 0  
Total operating expenses 213.3 158.6 411.2 300.0  
Operating Income (Loss) 103.5 55.0 179.1 91.1  
Assets 1,875.9 1,574.3 1,875.9 1,574.3  
Long-Lived Assets 691.1 587.4 691.1 587.4  
Capital Expenditure on Long-Lived Assets 27.4 161.9 63.8 187.4  
All Other Segment
         
Reconciliation from Segment Totals to Consolidated [Line Items]          
Product Sales 0 0   0  
Royalties 11.6 38.5 47.7 75.2  
Other Revenues 1.3 1.3 2.7 2.6  
Revenues 12.9 39.8 50.4 77.8  
Cost of Product Sales 0 0 0 0  
Research and Development 0 0 0 0  
Selling, General and Administrative 53.7 55.9 109.9 103.5  
Loss/(gain) on sale of product rights 0 0 0 0  
Reorganization Cost 4.8 5.3 8.0 6.9  
Integration and Acquisition Cost 0 0 0 0  
Total operating expenses 58.5 61.2 117.9 110.4  
Operating Income (Loss) (45.6) (21.4) (67.5) (32.6)  
Assets 734.4 1,213.1 734.4 1,213.1  
Long-Lived Assets 42.9 48.8 42.9 48.8  
Capital Expenditure on Long-Lived Assets $ 5.3 $ 2.1 $ 7.9 $ 4.0  
[1] Cost of product sales includes amortization of intangible assets relating to favorable manufacturing contracts of $0.4 million for the three months to June 30, 2011 (2010: $0.4 million) and $0.9 million for the six months to June 30, 2011 (2010: $0.9 million). Selling, general and administrative costs includes amortization for intangible assets relating to intellectual property rights acquired of $36.7 million for the three months to June 30, 2011 (2010: $33.8 million) and $72.7 million for the six months to June 30, 2011 (2010: $68.4 million).